PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Spasticity

Drugs in development · updated 30 October 2026

Spasticity: drugs in development

As of 30 October 2026 there are 8 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for spasticity. 4 are experimental, that is not yet approved in the United States.

8Active trials
4Experimental drugs
1Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
ArbaclofenIII1NCT05179577
BFB-101I–II1NCT06948019
BMS-986368II1NCT06782490
CorabotaseI–II1NCT04752774

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
DysportI–II1NCT04752774
Hyaluronidase-fihjHydase®, Amphadase®II1NCT03306615
Botulinum toxin type ANuceiva®Early I1NCT06811142
MethylphenidateConcerta, Relexxii®Early I1NCT05675098
ModafinilProvigil®Early I1NCT05675098
TizanidineOntralfy®, Zanaflex®Early I1NCT06666673

Sorted by most advanced phase and number of active trials.

All 10 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009128 “Muscle Spasticity”.

ItalianoFrançaisDeutsch